FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research report issued on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

Shares of NASDAQ:FGEN opened at $0.42 on Friday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The firm has a market capitalization of $42.80 million, a P/E ratio of -0.35 and a beta of 0.72. The stock has a 50 day moving average price of $0.36 and a 200-day moving average price of $0.66.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to the consensus estimate of $34.00 million. During the same period in the prior year, the company posted ($0.52) EPS. On average, equities analysts forecast that FibroGen will post -0.86 EPS for the current fiscal year.

Institutional Trading of FibroGen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the last quarter. Doheny Asset Management CA purchased a new stake in FibroGen during the 2nd quarter valued at $48,000. Accel Wealth Management boosted its stake in FibroGen by 117.5% during the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 51,645 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in FibroGen during the 2nd quarter valued at $89,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in FibroGen during the 2nd quarter valued at $130,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.